secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0001558370-23-009499
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path Q1 net loss $5.3M ($0.66/share); cash burns to $6.7M; clinical milestones Q2/3
--------------------------------------------------------------------------------

- Net loss $5.3M ($0.66/share) vs $3.4M ($0.47) Q1 2022; R&D spend doubled to $4.0M.
- Cash $6.7M at Mar 31, down from $10.4M Dec 31; net cash used in ops $3.7M.
- BP1001-A solid tumor trial initial cohort completion/data readout expected mid-2023.
- BP1002 relapsed/refractory AML cohort readout expected mid-2023.
- Prexigebersen Phase 2 AML: two cohorts exceeded min efficacy for expansion; interim analyses start Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000155837023009499/0001558370-23-009499-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000155837023009499/bpth-20230512x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-009499

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer